Merck & Co (MRK) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS
Merck & Co (NYSE:MRK) released its earnings data on Monday. The company reported $0.92 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.88 by $0.04, AnalystRatings.Net reports. The company had revenue of $11.03 billion for the quarter, compared to the consensus estimate of $11.19 billion.
A number of analysts have recently weighed in on MRK shares. Analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Sunday. Finally, analysts at BMO Capital Markets cut their price target on shares of Merck & Co to $48.00 in a research note to investors on Thursday, October 17th. They now have a “market perform” rating on the stock. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $50.96.
Merck & Co (NYSE:MRK) opened at 46.54 on Monday. Merck & Co has a 52 week low of $40.02 and a 52 week high of $50.16. The stock has a 50-day moving average of $47.92 and a 200-day moving average of $46.68. The company has a market cap of $136.2 billion and a price-to-earnings ratio of 27.87. Merck & Co also saw unusually large options trading on Friday. Stock investors acquired 17,568 put options on the stock. This represents an increase of approximately 214% compared to the average volume of 5,600 put options.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.